Identification of benzothiazones containing a hexahydropyrrolo[3,4-c]pyrrol moiety as antitubercular agents against MDR-MTB

IMB1603, a spiro-benzothiazone compound discovered by our lab, displayed potent anti-MTB activity in vitro and in vivo. In this study, we reported a series of new BTZs containing the hexahydropyrrolo[3,4-c]pyrrol moiety based on the structure of IMB1603. Among them, BTZs 11 and 24 displayed potent anti-MTB (MIC < 0.035 μM) and MDR-MTB (MIC, 0.053–0.102 μM) activity, good solubility (1.82–1.85 μg mL−1), and low cytotoxicity (CC50 > 200 μM), suggesting BTZs 11 and 24 may serve as promising candidates for further study. The molecular docking study of 11 toward DprE was also investigated, and revealed that 11 mimicked the binding pattern of PBTZ169 in the active site of DprE1.

[1]  S. Franzblau,et al.  Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents. , 2019, European journal of medicinal chemistry.

[2]  C. Daley.  The Global Fight Against Tuberculosis. , 2019, Thoracic surgery clinics.

[3]  G. Besra,et al.  Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones. , 2018, European journal of medicinal chemistry.

[4]  G. Ippolito,et al.  Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. , 2018, The Lancet. Infectious diseases.

[5]  P. Murumkar,et al.  Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. , 2018, Journal of medicinal chemistry.

[6]  Menghao Huang,et al.  Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. , 2018, European journal of medicinal chemistry.

[7]  Yuquan Wei,et al.  Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles , 2018, RSC advances.

[8]  R. Müller,et al.  Novel and revisited approaches in antituberculosis drug discovery. , 2017, Current opinion in biotechnology.

[9]  Fatih Köksal,et al.  New drugs for the treatment of Mycobacterium tuberculosis infection. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Xuefu You,et al.  Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents. , 2017, ACS medicinal chemistry letters.

[11]  Mingliang Liu,et al.  Design, synthesis and antitubercular evaluation of benzothiazinones containing an oximido or amino nitrogen heterocycle moiety , 2017 .

[12]  Richard E. Lee,et al.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis. , 2016, Advanced drug delivery reviews.

[13]  L. Chiarelli,et al.  Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043. , 2016, ACS medicinal chemistry letters.

[14]  S. Cole,et al.  DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. , 2015, ACS chemical biology.

[15]  S. Franzblau,et al.  Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043. , 2015, ACS medicinal chemistry letters.

[16]  Nicola J. Ryan,et al.  Delamanid: First Global Approval , 2014, Drugs.

[17]  T. Buclin,et al.  Towards a new combination therapy for tuberculosis with next generation benzothiazinones , 2014, EMBO molecular medicine.

[18]  R. Read,et al.  Supplementary Materials for Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis , 2012 .

[19]  Johnny X. Huang,et al.  Identification of antitubercular benzothiazinone compounds by ligand-based design. , 2012, Journal of medicinal chemistry.

[20]  P. Li,et al.  Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation , 2011, Antimicrobial Agents and Chemotherapy.

[21]  Vadim Makarov,et al.  Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. , 2010, Journal of the American Chemical Society.

[22]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.